The outcomes used in clinical trials of pulmonary arterial hypertension (PAH) don’t fully reflect the priorities of patients and clinicians, a new study asserts. The study, “‘It’s that invisible illness’: Patient and clinician perspectives on outcomes in pulmonary arterial hypertension treatment,” was published in the journal…
News
Tenax Therapeutics has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO), indicating that a patent for TNX-103 — oral levosimendan — is to be granted. The patent is expected to cover the use of TNX-103 for treating people with pulmonary hypertension and…
Janssen Pharmaceuticals has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of a combination tablet containing both macitentan and tadalafil as a treatment for pulmonary arterial hypertension (PAH). “People with PAH are often prescribed numerous medicines to manage their condition, so the potential…
Treatment with AER-901, an inhaled formulation of imatinib that Aerami Therapeutics is developing as a treatment for two forms of pulmonary hypertension, was generally well-tolerated in a Phase 1 study conducted with healthy volunteers. That’s according to safety data presented by Aerami at the 2023 American Thoracic Society…
AV-101, an inhaled formulation of imatinib for people with pulmonary arterial hypertension (PAH) now being tested in clinical trials, was found in a series of experiments in animal models to result in better lung exposure than oral formulations of the medication. By offering direct delivery to the lungs, AV-101’s…
Treatment with KER-012, an experimental therapy Keros Therapeutics is developing to treat pulmonary arterial hypertension (PAH), lowered markers of heart damage, fibrosis, and inflammation in a Phase 1 clinical trial that tested the therapy in healthy postmenopausal women. Keros presented the findings at the American Thoracic Society (ATS)…
The proportion of people with pulmonary arterial hypertension (PAH) who start on a combination of medications after they’re diagnosed is low, but has increased over the last decade, a study shows. The findings were presented at the 2023 American Thoracic Society (ATS) International Conference, in the poster, “…
Team PHenomenal Hope will host its inaugural symposium — PHenomenal Hope 2023: Knowledge, Research & Advocacy in PH — on Dec. 15 in Boston, allowing renowned experts, young researchers, and healthcare providers to share efforts on pulmonary hypertension (PH) clinical research and care. “Team PHenomenal Hope has grown…
People with pulmonary arterial hypertension (PAH) and their caregivers place different value on the parameters used to evaluate clinical worsening in trials, according to the findings of a survey in Canada. Patients attributed significant importance to lacking clinical improvement, needing long-term oxygen therapy, and any decrease in health-related quality…
MRE-269, an active metabolite of Uptravi (selexipag), is more effective at stopping the growth of lung cells from people with chronic thromboembolic pulmonary hypertension (CTEPH) than it is in healthy lung cells, a study found. Researchers also discovered that MRE-269 may do this by increasing the activity of ID1…
Gossamer Bio is planning to soon launch a Phase 3 clinical trial to test its experimental inhaled therapy seralutinib (GB002) in people with pulmonary arterial hypertension (PAH). “We remain on track to begin our Phase 3 clinical trial of seralutinib in the coming months, moving one step closer…
Members from two families with diagnosed or suspected pulmonary arterial hypertension (PAH) each carried two copies of mutations that map to the CAPNS1 gene and are likely rare causes of the disease, according to a study. The study, “Biallelic variants in the calpain regulatory subunit CAPNS1 cause pulmonary…
